JAK1 and diffuse large B-cell lymphoma: Thus, small molecule inhibitors that only partially inhibit STAT1, such as of JAK1/JAK2 inhibitors, or indirectly inhibit STAT1 by targeting a subset of STAT1-dependent oncogenic signaling pathways, such as small molecule inhibitors of ARTD9 and DTX3L, might be the more suitable drugs for targeting the oncogenic functions of STAT1 in DLBCL.